Showing 4791-4800 of 9576 results for "".
- Triple-Combo Gel Reduces Acne Lesions, Scarring, and PIH Over 6 Months: Studyhttps://practicaldermatology.com/news/study-triple-combo-gel-reduces-acne-lesions-scarring-and-pih-over-6-months/2474438/Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) was associated with significant long-term efficacy and safety in the treatment of moderate acne and associated sequelae, results from a new 24-week open-label study indicate.
- SEEN Expands Pediatric Line with Fragrance-Free Baby Shampoo and Body Washhttps://practicaldermatology.com/news/seen-expands-pediatric-line-with-fragrance-free-baby-shampoo-and-body-wash/2474436/SEEN has announced the launch of SEEN Baby 2-in-1 Fragrance Free, a new ultra-gentle shampoo and body wash designed specifically for infants and young children with sensitive or eczema-prone skin, according to a news release from the manufacturer.
- Study Shows Prognostic Value of 40-GEP in Advanced cSCChttps://practicaldermatology.com/news/study-shows-prognostic-value-of-40-gep-in-advanced-cscc/2474383/A new multi-institutional study indicates that a 40-gene expression profile (40-GEP) test with traditional staging enhances risk stratification for cutaneous squamous cell carcinoma (cSCC), even among patients already categorized as high- or very-high-risk using Na
- FDA Gives Nod to First Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fda-gives-nod-to-first-cell-based-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2474382/The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (prademagene zamikeracel, pz-cel), making it the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The approval addresses a major unmet clinical nee
- EARLY: Guselkumab Use Supported in PsO Patients With HBV, Cancer, or Heart Diseasehttps://practicaldermatology.com/news/early-guselkumab-use-supported-in-pso-patients-with-hbv-cancer-or-heart-disease/2474211/Guselkumab, an IL-23 inhibitor approved for moderate-to-severe psoriasis, showed long-term safety in patients with complex comorbidities—including chronic infections, prior malignancies, and cardiovascular disease—according to findings from the EARLY Study.
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Kenvue’s Ricciardone Explains New Data on the Value of Teamwork in Moisturizers and Retinoidshttps://practicaldermatology.com/news/Kenvues-Ricciardone-Explains-New-Data-Value-Teamwork-Moisturizers-Retinoids/2474166/Data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, supported the “full sandwich” moisturizer method for new retinoid users who may experience sensitivity from retinization during the skin acclimation period while also suggesting that Neutrogena® H
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.
- Obesity and Epidermal Innate Immunity Linked to Resistance to Biologic Therapy in Psoriasishttps://practicaldermatology.com/news/obesity-and-epidermal-innate-immunity-linked-to-resistance-to-biologic-therapy-in-psoriasis/2473927/Patients with severe plaque psoriasis who are overweight are more likely to experience resistance to biologic therapies, according to new findings The study researchers designed and conducted a cross-sectional study at Gachon
- Report: Seborrheic Dermatitis Market Poised for Expansion through 2032https://practicaldermatology.com/news/report-seborrheic-dermatitis-market-poised-for-expansion-through-2032/2473856/The seborrheic dermatitis market has been projected to grow through 2032, according to a new report from Delveinsight. The expansion in market size coincides with the CAGR study, according to a press release. The report notes the recent approval of roflumilast foam 0.3% (ZORYVE, Arcutis) f